CARO 2016 S29 _________________________________________________________________________________________________________ cardiac four-dimensional CT (4D-CT) synchronized to the electrocardiogram were obtained in treatment position, using a prospective sequential acquisition method including the extreme phases of systole and diastole. On a MimVista® image registration workstation, dose distributions were transferred to the cardiac 4D-CT. The left coronary artery, left ventricle and heart were contoured on both phases of the cardiac cycle. The maximum and minimum doses to the left coronary, left ventricle and heart were compared using a bilateral paired Student T test. Results: Preliminary data from the first eight patients enrolled are presented. Median age was 60 years (56-71) and median planned dose to the left breast was 42.56 in 16 fractions (16)(17)(18)(19)(20). For the left coronary artery, mean dose, V5 and V20 in systole versus diastole were 6.1 Gy versus 7.9 Gy (p = 0.02), 37% versus 48% (p = 0.02) and 10% versus 16% (p = 0.04), respectively. For the left ventricle, mean dose, V5 and V20 in systole versus diastole were 1.3 Gy versus 1.6 Gy (p = 0.005), 6% versus 9% (p = 0.03) and 1% versus 2% (p > 0.1), respectively. For the whole heart, mean dose, V5 and V20 in systole versus diastole were 0.9 Gy versus 1.3 Gy (p = 0.005), 21 cc versus 32 cc (p = 0.07) and 4 cc versus 5 cc (p > 0.1), respectively. Conclusions: Beyond DIBH, systolic irradiation would be associated with a further reduction in V5, V20 and mean dose to the left coronary artery, as well as a reduction in V5 and mean dose to the left ventricle and heart as a whole. The potential clinical impact of this reduction as well as the feasibility of cardiac gated irradiation are to be further investigated.
Purpose: Non-melanoma skin cancers occurring in areas with irregular contours like the ear pose challenges in effectively delivering a therapeutic radiation dose using electrons. As electrons deliver dose at a depth, a tissue equivalent material called bolus must be placed on the skin so that therapeutic dose is delivered to the tumour. Commercially available bolus materials lack the ability to conform to a patient's specific anatomy in areas with irregular contours. Such shortcomings can create air cavities between the tumour and bolus, and ultimately lead to treatment inaccuracy. A custom bolus can be made from wax, but this also has shortcomings. It is labour intensive and challenging to create a wax bolus with uniform specified thickness and minimal air gaps. As an alternative, we have developed a technique of generating soft silicone bolus, which conforms to irregular anatomy, using an optical scanner and rigid material 3D printer. Methods and Materials: Volunteer specific anatomy of the ear was acquired using a consumer-grade optical scanner (3D Systems, Sense). A three-dimensional model of each volunteer was exported to a mesh editing software (Autodesk, MeshMixer v2.9) where replica of the ear anatomy was designed. This replica was exported as an STL file to software controlling the printer (Repetier-Host), converted to gcode (Slic3r) and printed on a consumer-Grade 3D printer (MakerGear, M2). This replica served as a rigid mould for silicone rubber. The result was a soft bolus with one side flat and the other side perfectly fitting the ear. Results: The soft silicone bolus created by this technique perfectly fit the anatomy, was of desired thickness, comfortable to put on with no sharp edges. There were no air gaps visible. No air bubbles were found using x-ray imaging. Dosimetric studies were done on the silicone rubber and it was found acceptable to be used as a bolus material. Conclusions: Using an optical scanner and 3D printer enables us to create a soft, flexible silicone conformal bolus which is cost effective. Silicone bolus accurately fits with no air gaps and is better for irregular contours than a commercial or wax bolus. It is also better than a hard plastic 3D printed bolus for areas where a rigid bolus is difficult to use or causes patient discomfort. This approach does not require intensive training and enhances the patient experience as they can have an optical scan on the day of clinical appointment and directly come on the day of treatment. It also has potential to save treatment machine time because the setup time is anticipated to be reduced as the complexity of set up is greatly decreased. From 2003 From -2012 consecutive patients were treated with intraoperatively planned LDR prostate brachytherapy without external beam radiotherapy at our centre. Dosimetric planning targets were uniform with a goal of D90 prostate > 180 Gy, V150 > 74%, V200 > 37%, V140 urethra < 24% and V150 urethra < 3%. Patients were followed according to a protocol every 6 months for the first three years then annually. For each patient, all data were entered into a central database prospectively and retrospectively verified by reviewing a centralized electronic health record that comprehensively captures all interventions performed and visitations to any medical centre in the province of Alberta, Canada. Urinary interventions included cystoscopy, transurethral resection of the prostate, urethral dilatation or catheterization for urinary retention or hematuria attributable to brachytherapy. These patients were then isolated and compared with the remaining control cohort using tests of proportions and multivariate analysis as appropriate. Results: Median follow up was 7.1 years (range: 2.5 -12.5). Intervention for RTOG Grade 3 toxicity was encountered in 51 patients (7%). Cystoscopy was done in 31 patients (4.3%) for RT related hematuria or obstruction. TURP was performed in 14 patients (1.9%) with a median time from implant of 20.4 months (range, 3-86) and dilatation for RT toxicity in six patients (0.8%) with a median time of 29 months (range, 20-85). Median preimplant volume was 37.1 cc (20.2 -53.0) in patients having intervention for Grade 3 toxicity and 33.7 cc (13.2 -66.9) in those without [p < 0.05]. Time from biopsy to implant, pretreatment AUA symptom score, PSA, clinical stage, use of hormones, and urethral dosimetry did not predict for urinary intervention in our analysis.
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Conclusions:
Urinary intervention rates following intraoperatively planned LDR prostate brachytherapy are low overall at 7%. The strength of our study is the ability to review all hospital records in our health region to completely capture any urinary intervention due to an integrated electronic health records system.
